Methicillin Resistant Staphylococcus Aureus Drugs Market Analysis | CMI

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET ANALYSIS • Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, By Drug class (Glycopeptides and Lipoglycopeptides, Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2018 - 2026 • The global methicillin-resistant staphylococcus aureus (MRSA) drugs market is estimated to be valued at US$ 922.2 million in 2018, and is expected to register a CAGR of 4.1% during the forecast period (2018–2026).

3. Figure 1. Global Methicillin-resistant Staphylococcus aureus (MRSA) drugs Market Share (%), By Drug Class, (2018 & 2026)

4. Market Drivers • Increasing Regulatory Approvals for Drugs Is Expected to Drive Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Growth • Approvals and launches of affordable generic medication is expected to drive the global methicillin-resistant Staphylococcus aureus (MRSA) drugs market growth over the forecast period. For instance, in 2015, Glenmark Pharmaceuticals received the approval from the U.S. Food and Drug Administration (FDA) for the generic version of the anti-bacterial drug, Zyvox. Moreover, in 2015, Allergan Plc. received the U.S. FDA approval for supplemental new drug application (sNDA) to update the label of Teflaro (ceftaroline fosamil) for treating adult patients with acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP). • Furthermore, strategic agreements and collaborations by market players regarding distribution of MRSA drugs are expected to drive the market growth. For instance, in 2016, Basilea Pharmaceutica Ltd. entered into a supply, distribution, and license agreement with Grupo Biotoscana S.L., for Basilea's antifungal CRESEMBA (isavuconazole) and antibiotic Zevtera (ceftobiprole) in 19 countries of Latin America along with Brazil, Mexico, Argentina, and Colombia.

5. Market Restraints • However, declining patient pool having infections caused by MRSA pathogen is expected to restrain growth of the global methicillin-resistant staphylococcus aureus (MRSA) drugs market. According to the Centers for Disease Control and Prevention, hospital associated MRSA infections declined by 54% between 2005 and 2011 owing to increasing awareness about personal and public hygiene among the populace. This, in turn, is expected to reduce demand for the drugs.

6. Market Regional Analysis • Regional segmentation of the global methicillin-resistant staphylococcus aureus (MRSA) drugs market includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. • Among region, North America is expected to hold a dominant position in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market, and is expected to witness significant growth over the forecast period, owing to increasing health awareness, favorable reimbursement scenario, rising healthcare expenditure, and increasing number of approvals and launches of MRSA drugs. For instance, in 2016, Allergan Plc. received the U.S. Food and Drug Administration (FDA) approval for its supplemental new drug application (sNDA) to update the label for Dalvance (dalbavancin) for injection. • Moreover, Asia Pacific is expected to witness significant growth over the forecast period, owing to a larger patient pool, and expansion strategies adopted by market players to increase their market presence. For instance, in 2017, Basilea Pharmaceutica Ltd. entered into a licensed agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. for expansion of Basilea's antibiotic Zevtera, a broad spectrum anti-bacterial, which can address MRSA in China, Hong Kong, and Macao. • Furthermore, Europe is projected to witness significant market growth owing to launches and approvals of new drugs. For instance, in 2017, Cardiome Pharma Corp. launched Xydalba in Sweden, Finland, and the Republic of Ireland. Xydalba is approved by the European Medicines Agency (EMA) for treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults.

7. Figure 2: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Share (%), By Region, (2018 & 2026)

8. Market Competitive Landscape • Key players operating in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market include Merck & Co, Inc., Pfizer, Inc., Allergan Plc., Teva Pharmaceutical Industries ltd, Melinta Therapeutics, Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics Plc., Paratek Pharmaceuticals, Inc., Debiopharm International S.A., and Innovation Pharmaceuticals Inc.

9. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • Reference : https://www.coherentmarketinsights.com/market-insight/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-1538

10. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

11. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

12. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/